[1] MA H M, LIU X, ZHANG M Y, et al. Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms[J]. Mol Biol Rep, 2021, 48(3):2803-2815. [2] 傅柳,尚广彬,陈中,等.中药逆转肝纤维化进程的研究概况[J].时珍国医国药, 2021, 32(4):944-948. [3] 邓羊羊,葛善飞,余燕青,等.肝纤维化相关细胞信号转导通路及潜在治疗策略[J].临床肝胆病杂志, 2020, 36(5):1141-1145. [4] MARTÍ-RODRIGO A, ALEGRE F, MORAGREGAÁB, et al.Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5):920-932. [5] WANG Z, LI J A, XIAO W A, et al. The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis[J]. Lab Invest, 2018, 98(12):1600-1613. [6] 韩玫,李贞,周舟,等.艾灸联合柴胡疏肝散治疗慢性乙型肝炎肝纤维化[J].中医学报, 2021, 36(7):1562-1567. [7] 吴庆,曹文富,张永越,等.益气化瘀化痰法制剂对CCL4所致肝纤维化大鼠肝组织KLF15、NF-κB及下游炎症因子的影响[J].中药新药与临床药理, 2018, 29(5):557-563. [8] LIEM I K, ZAKIYAH Z, OKTAVINA R, et al. Comparison of two methods of 2AAF/CCL4 exposure to induce rat animal model of chronic liver injury[J]. EJKI, 2021, 8(3):164-171. [9] XU S Z, MAO Y Q, WU J Y, et al. TGF-β/Smad and JAK/STAT pathways are involved in the anti-fibrotic effects of propylene glycol alginate sodium sulphate on hepatic fibrosis[J]. J Cell Mol Med, 2020, 24(9):5224-5237. [10] ÖZTÜRK AKCORA B, VASSILIOS GABRIËL A, ORTIZPEREZ A, et al. Pharmacological inhibition of STAT3 pathway ameliorates acute liver injury in vivo via inactivation of inflammatory macrophages and hepatic stellate cells[J]. FASEB Bioadv, 2020, 2(2):77-89. |